PT  - JOURNAL ARTICLE
AU  - Balkova, Bronislava
AU  - Dlouha, Beata
AU  - Klusackova, Pavlina
AU  - Lebedova, Jindriska
AU  - Hurtova, Lenka
TI  - Bronchoprovocation challenge testing – The estimation of FEV1 decline
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p3508
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p3508.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p3508.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Background: Methacholine and histamine bronchoprovocation challenge (BPC) is an important tool in the diagnosis of bronchial hyperreactivity (BHR). Some patients respond to BPC by a significant and fast drop in forced expiratory volume in one second (FEV1). The aim of the study was to evaluate which baseline anamnestic data correlates with a fast and severe drop in FEV1.Methods: BPC was performed in each of 1375 patients presenting with suspected bronchial asthma (BA) of either occupational (OA) - 207 patients (15%) or non-occupational origin (1168 patients - 85%). The consequential impact of the following parameters on FEV1 drop was also checked: age, sex, respiratory difficulties (dyspnoea, irritating cough, wheezing and allergic rhinitis symptoms), atopy, past medical history (PMH) of respiratory infection, smoking, chronic bronchitis. A 30% or higher FEV1 drop at bronchoprovocant dosages or concentrations lower than the planned cumulative dose or a 40% or higher FEV1 drop after inhalation of the whole bronchoprovocant dose was considered as severe.Results: A severe FEV1 drop was found in 248 persons (18%), of which 201 patients (14.6%) were finally diagnosed with BA (52 patients with OA, 149 with non OA origin). Statistically significant FEV1 drop was found in both subgroups among patients with a PMH of whistling, among patients with atopy and smokers.Conclusion: Caution is recommended when performing BPC in some patients, particularly in those with suspected asthma who are smokers, diagnosed with atopy and those with a PMH of wheezing. These patients may experience greater discomfort from bronchial obstruction and therefore, the provocational dose may need to be increased at a slower rate.